NFE2L2 and Fuchs endothelial corneal dystrophy: Sulforaphane is another Cys-151 modifier that has been suggested as a therapy for FECD as it has been demonstrated to reduce apoptosis of FECD-CEC through the re-establishment of the Nrf2 pathway [118].